Indberetningsfrekvensen af leversvigt med dødelig udgang i forbindelse med cerivastatin var 2- 6 gange lavere end for de øvrige statiner.
The reporting rate of fatal hepatic failure with cerivastatin was 2-6 times lower than that of the other statins.